Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434843 | 0.93 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1MAPTCRHBPCRHR2 | |
| SCHEMBL2530387 | 0.93 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1MAPTCRHBPCRHR2 | |
| SCHEMBL14334111 | 0.83 | PDK1 (0.43) | L3MBTL1ALDH1A1MAPTCRHBPCRHR2 | |
| SCHEMBL2532268 | 0.82 | ALDH1A1 (0.49) | ALDH1A1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2530388 | 0.82 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1MAPTCRHBPCRHR2 | |
| SCHEMBL30365148 | 0.80 | HPGD (0.34) | L3MBTL1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL21806057 | 0.80 | HPGD (0.34) | L3MBTL1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL3385442 | 0.79 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1MAPTCRHBPCRHR2 | |
| SCHEMBL28082082 | 0.78 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL28082084 | 0.78 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117049938-B | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117049938-A | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-117049938-B | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117049938-B | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117049938-A | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-117049938-A | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-8481566-B2 | 4-Fluoro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; for treatment of psychotic disorders and cognitive impairment | GLAXO GROUP LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8283364-B2 | Psyvhological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| EP-1943230-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1943230-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| WO-2007036715-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | L3MBTL1 821/4885ALDH1A1 1459/4885MAPT 2089/4885 |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | CHRM1, CHRM2, CHRM5 | L3MBTL1 681/4885ALDH1A1 1591/4885MAPT 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.